Semaglutide

Semaglutide is a modified peptide analogue of human glucagon-like peptide-1 with an extensive published research literature in GLP-1 receptor pharmacology, incretin signaling, and downstream metabolic pathways.

Binds and activates the GLP-1 receptor, increasing glucose-dependent insulin secretion, suppressing inappropriate glucagon secretion, slowing gastric emptying, and influencing central satiety pathways.

Substantial controlled human evidence and multiple FDA-approved drug products.

Level I, Established human evidence

Evidence from approved pharmaceutical products cannot be used to establish the purity, sterility, potency, or clinical equivalence of an independently supplied research material.

Approved-product labeling includes gastrointestinal adverse reactions, pancreatitis and gallbladder warnings, hypoglycemia risk in some combinations, and a boxed warning concerning thyroid C-cell tumors observed in rodents.

The active ingredient is used in FDA-approved prescription drugs; a Cendrix research material is not an FDA-approved drug.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.